Editas Medicine Advances Gene-Editing Therapy EDIT-401
Cambridge, Massachusetts – September 2, 2025 Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene-editing biotechnology company, has nominated EDIT-401,...
AML
Advertisement
Sumitomo Pharma Unveils Promising Data in Blood Cancers
Marlborough, Massachusetts – November 3, 2025 Sumitomo Pharma America, Inc. (SMPA) announced compelling new investigational data from multiple clinical...
BioNTech Advances Oncology Pipeline and Strengthens 2025 Financial Outlook
MAINZ, Germany, November 3, 2025 — BioNTech SE (Nasdaq: BNTX) reported its third quarter 2025 financial results, highlighting significant...
Aptose to Present Promising Tuspetinib AML Data at 2025 ASH Meeting
SAN DIEGO and TORONTO, November 3, 2025 — Aptose Biosciences Inc. (TSX: APS), a clinical-stage precision oncology company, announced...
AbbVie Submits BLA for Pivekimab Sunirine to FDA for Rare Blood Cancer
North Chicago, IL – September 30, 2025 – AbbVie (NYSE: ABBV) announced the submission of a Biologics License Application...
Advertisements
Kura and Kyowa Kirin Launch Trial Targeting FLT3/NPM1 AML
SAN DIEGO and TOKYO, Oct. 1, 2025 — Kura Oncology and Kyowa Kirin have announced the first patient dosing...
Advertisement
